News >

Varlitinib Misses PFS, ORR Endpoints in Biliary Tract Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Nov 12, 2019

Carl Firth, chief executive officer of Aslan Pharmaceuticals

Carl Firth

Varlitinib combined with capecitabine (Xeloda) did not improve progression-free survival (PFS) nor overall response rate (ORR) compared with capecitabine/placebo as a second-line treatment in patients with biliary tract cancer (BTC), missing both primary endpoints of the phase III TreeTopp trial (NCT03093870).1

Results showed that patients who received varlitinib and mFOLFOX6 had an average tumor shrinkage of 22.0% after 12 weeks versus 12.5% in those who received mFOLFOX6 alone, which did not reach statistical significance. Following review of 17 PFS events to date, data did show a trend toward an improvement in PFS in the varlitinib arm.

References

  1. ASLAN Pharmaceuticals announces topline results from TreeTopp global pivotal study of varlitinib in biliary tract cancer. ASLAN Pharmaceuticals. Published November 11, 2019. https://bit.ly/2pU10gi .Accessed November 11, 2019.
  2. ASLAN Pharmaceuticals announces study results from phase 2 study of varlitinib in first-line gastric cancer. Aslan Pharmaceuticals. Published January 14, 2019. https://bit.ly/2stwaIZ?rel=0" . Accessed January 14, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x